Coronavirus

This examination of vaccine introductions worldwide reveals significant gaps in access, especially in low-income countries.

Researchers investigated abatacept, cenicriviroc, and infliximab, but found that these medications did not significantly impact the time to recovery from COVID-19 pneumonia compared to placebo.

These study findings highlight higher in-hospital mortality rates for patients with preventable conditions during COVID-19.

The findings showed that heterologous vaccination, or mixing different vaccines, was safe and effective, with the Novavax vaccine (NVX-CoV2373) providing enhanced protection against the Omicron variant.

This variant, which is an ancestor of Omicron, is an emerging variant that is being seen most frequently in Utah, California, and New York State.

A small study explored the connection between Postural Orthostatic Tachycardia Syndrome (POTS) and the COVID-19 condition.

Patients who perceived brain fog within 4 weeks of COVID-19 infection were twice as likely to report symptoms of long COVID than patients without cognitive deficits.

There was a lower risk of Omicron infection for each 10-fold increase in preinfection IgG, and for each 2-fold increase in neutralizing antibody titers.

In Indiana, COVID-19 patients with chronic obstructive pulmonary disease, cardiovascular disease, and type 2 diabetes had significantly higher mortality rates than COVID-19 patients without these comorbidities.

The strain, identified as EU11, accounts for 1.7% of cases nationwide in the United States.

Non-enveloped viruses were resistant to all types of wash products and duration tested, including synthetic soaps, such as the ones typically used in hospitals.

Even low levels of air pollution make COVID-19 worse, this study found. Air pollution exposure was associated with more severe disease, longer hospitalization periods, and an increased likelihood of intensive care admission.

The vaccine manufacturer has incorporated spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for its mRNA-1273.815 COVID-19 vaccine.

While COVID-19 patients had a higher risk of venous thromboembolic disease compared to influenza and sepsis patients, the risk of other adverse outcomes was comparable.

ABNCoV2, a non-adjuvanted COVID-19 booster vaccine by Bavarian Nordic, demonstrates promising results in phase 2 trials. The vaccine generates strong immune responses, neutralizing multiple variants of concern, including Beta, Delta, and Omicron.

In a large observational study, significant information was obtained about protection against acute infection and disease severity in this age group.

This past weekend, vaccine scientist and physician Peter Hotez, MD, PhD, was stalked outside his home after facing online scrutiny from Twitter CEO Elon Musk and controversial podcaster Joe Rogan. His story is severe, but Hotez is far from the first health advocate to be harassed online since the COVID-19 pandemic.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 2023-2024 COVID-19 vaccines should be updated to a monovalent XBB strain.

"It does take the immune system a while to build up antibodies and recover," said Madeline King-Patel, PharmD, BCIDP, "So you don't want to give the vaccines too close to each other, or you're not going to get the full benefits."

A new retrospective study found non-oxygen-dependent COVID-19 patients were more likely to experience this phenomenon if they were immunocompromised, receiving concomitant corticosteroids, or had comorbidities.

This study compares the mortality rates between Canada's public health care and the US private system, highlighting the complexities of pandemic response.

As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.

COVID-19 and CMV coinfection caused the premature aging of immune systems, leading to a greater risk of cardiovascular disease at an earlier age, the study authors said.

Following household COVID-19 transmissions for over 3 years, investigators found that 70.4% had a pediatric index case.

How does the diagnosis rate of mental health disorders after COVID-19 compare to that of other respiratory infections?

The FDA's decision to approve Abrysvo was based on data from a Phase 3 clinical trial, which demonstrated the RSV vaccine's efficacy, immunogenicity, and safety in adults aged 60 and older.

Neutralizing antibodies were initially lowest among Janssen vaccine recipients, but this all changed 6 months after vaccination.

European medical committee offers favorable opinion for people with all forms of renal impairment including those on dialysis.

Sleep as a shield: A new study reveals that sleeping well before COVID-19 infection reduces the risk of post–COVID-19 condition (long COVID).

Analysis of symptoms present six months or more after SARS-CoV-2 infection was used to develop a composite scoring framework for identifying postacute sequelae of SARS-CoV-2 infection (PASC) as a new condition.